Get the Stockscreener App
6.50
1.07%
-0.07
Imunon Inc stock is traded at $6.50, with a volume of 99,949.
It is down -1.07% in the last 24 hours and down -20.09% over the past month.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
See More
Previous Close:
$6.57
Open:
$6.6
24h Volume:
99,949
Relative Volume:
0.11
Market Cap:
$16.34M
Revenue:
$500.00K
Net Income/Loss:
$-19.45M
P/E Ratio:
-3.4392
EPS:
-1.89
Net Cash Flow:
$-18.22M
1W Performance:
+1.56%
1M Performance:
-20.09%
6M Performance:
-45.77%
1Y Performance:
-59.97%
1-Day Range:
$6.4812
$6.96
1-Week Range:
$6.171
$6.96
52-Week Range:
$4.8261
$41.22
Imunon Inc Stock (IMNN) Company Profile
Name
Imunon Inc
Sector
Industry
Phone
(609) 896-9100
Address
997 LENOX DRIVE, LAWRENCEVILLE
Compare IMNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNN
Imunon Inc
|
6.50 | 16.34M | 500.00K | -19.45M | -18.22M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Imunon Inc Stock (IMNN) Latest News
Imunon Inc. Rebounds From Oversold Zone — Now WhatDollar Strength & Verified Entry Point Detection - newsyoung.net
Trend Reversal Possible in Imunon Inc. Charts IndicateJuly 2025 Momentum & Weekly Market Pulse Updates - kangso.co.kr
Is Imunon Inc. trading at a discountJuly 2025 Catalysts & Fast Moving Stock Watchlists - kangso.co.kr
Is Imunon Inc. a strong candidate for buy and hold2025 Market Outlook & Fast Moving Trade Plans - classian.co.kr
Sentiment analysis tools applied to Imunon Inc.Market Trend Review & AI Driven Stock Reports - Newser
Is a relief rally coming for Imunon Inc. holders2025 Fundamental Recap & Daily Technical Forecast Reports - Newser
What candlestick patterns are forming on Imunon Inc.July 2025 Analyst Calls & Proven Capital Preservation Methods - Newser
Earnings Chart Overlay Points to Imunon Inc. UpsideJuly 2025 Price Swings & Real-Time Volume Trigger Notifications - sundaytimes.kr
IMUNON launches up to $9.75M securities offering - MSN
Imunon, Inc. Advances Phase 3 Trial for Innovative Cancer Treatment - MSN
Will breakout in Imunon Inc. lead to full recovery2025 Breakouts & Breakdowns & Consistent Profit Alerts - Newser
Tools to monitor Imunon Inc. recovery probabilityWeekly Profit Report & Growth Focused Entry Reports - Newser
How to escape a deep drawdown in Imunon Inc.2025 Geopolitical Influence & AI Enhanced Trading Signals - Newser
How Imunon Inc. stock performs during market volatilityPortfolio Profit Report & Fast Gain Swing Alerts - Newser
What are the future prospects of Imunon Inc.July 2025 Short Interest & Free Fast Gain Swing Trade Alerts - mustnews.co.kr
Can Imunon Inc. Regain Lost Ground This QuarterTrade Entry Summary & Real-Time Volume Analysis - classian.co.kr
Trendlines Converge — Decision Point for Imunon Inc.Market Risk Summary & Fast Momentum Stock Entry Tips - sundaytimes.kr
Imunon, Inc.’s Phase II Study on IMNN-001: A Potential Game-Changer in Ovarian Cancer Treatment? - TipRanks
Imunon, Inc.’s Ongoing Clinical Trial: Potential Game-Changer for Ovarian Cancer Treatment? - TipRanks
Is Imunon Inc. meeting your algorithmic filter criteriaJuly 2025 Recap & Capital Protection Trade Alerts - Newser
New Product Launches: Will They Boost Imunon Inc. Stock in 2025Free Growth Based Stock Signal Screener - Newser
Imunon, Inc. Advances Cancer Treatment with Phase 3 Trial of IMNN-001 - TipRanks
Imunon Inc. stock momentum explainedValue Investing Checklist with Entry Signals - Newser
Can Imunon Inc. outperform under higher oil pricesMassive Earnings Growth Picks - sisaissue.com
Can Imunon Inc. Bounce Back From Weekly LowStock Market Watch With Alerts Shows Unusual Activity - beatles.ru
How high can Imunon Inc. stock goLong Hold Investment Strategy with Growth Focus - Newser
Imunon, Inc. Earnings Call Highlights Progress and Challenges - MSN
Imunon (NASDAQ:IMNN) Upgraded by Wall Street Zen to Hold Rating - Defense World
Analysts Set Expectations for Imunon Q3 Earnings - Defense World
IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial… - Zacks Small Cap Research
Is now a turning point for Imunon Inc.Free Value Investing Picks With Stability - Newser
Imunon, Inc. shares fall 4.57% intraday despite announcing a 15% stock dividend payment. - AInvest
Imunon, Inc. (NASDAQ:IMNN) Q2 2025 Earnings Call Transcript - Insider Monkey
Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Ad - GuruFocus
IMUNON, Inc. Reports Progress in Cancer Therapy - TipRanks
Imunon Q2 2025 Earnings Call Transcript - MarketBeat
Imunon outlines rapid OVATION 3 Phase III trial launch and initiates 15% stock dividend to support shareholder value - MSN
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call - GlobeNewswire
IMUNON Announces 15% Stock Dividend, Advances Phase 3 Ovarian Cancer Trial | IMNN Stock News - Stock Titan
Earnings call transcript: Imunon Q2 2025 highlights EPS miss, stock dips - Investing.com Canada
Earnings call transcript: Imunon Q2 2025 highlights EPS miss, stock dips By Investing.com - Investing.com South Africa
Imunon's Q2 2025 Earnings: A Catalyst-Driven Path to Re-Rating? - AInvest
Imunon's Q2 2025 Earnings Call: Key Contradictions in Phase III Trials and Partnership Strategies - AInvest
Imunon reports Q2 EPS ($2.15), consensus ($4.99) - TipRanks
Imunon Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Imunon, Inc. SEC 10-Q Report - TradingView
IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Transcript : Imunon, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Insights Into Imunon's Upcoming Earnings - 富途牛牛
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025 - The Globe and Mail
Imunon Inc Stock (IMNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):